



dr. van haeringen laboratorium b.v.

a VHLGenetics company

MAU Urdiales Muro
Azarcones 4
45514 Quismondo
SPAIN
Customer number 109689

Through: LABOCOR, S.L.
Alamillo 41 41
ES-28770 COLMENAR VIEJO (MADRI
SPAIN

Analysis Certificate

Animal data

Name: D´SPAIN FUEGO NEGRO DONNA KARAN
Date of birth: 12.11.2020
Sexe: Female
Chip number: 941000026055518
Breed: Unknown

Sample data

VHL_ID: H532599
Test ID-nr: 527173 1
Material: Swab

H699 - Hereditary Cataract 2 (HC) -HSF4 - Date of test: 24.01.2022

Testresult: NORMAL

H724 - L2-HGA - Date of test: 24.01.2022

Testresult: NORMAL

H811 - Hyperuricemia (HUU) - Date of test: 24.01.2022

Testresult: NORMAL

H673 - Degenerative Myelopathy (DM) - Date of test: 02.02.2022

Testresult: NORMAL

H847 - Coat Colour D-Locus Improved (MLPH) - Date of test: 24.01.2022

Testresult: D/D

H919 - Hiplaxity 1 - Date of test: 24.01.2022

Testresult: N/N

H421 - Hiplaxity 2 - Date of test: 24.01.2022

Testresult: N/N

VHL exercises the utmost care in performing each of its engagements. No party other than the principal may derive any rights from the results of these engagements, and the principal expressly indemnifies VHL in respect of any third-party claims. VHL policy provides that any complaints must be received within eight days of the completion of an engagement and imposes restrictions on liability. In that respect, VHL refers to its General Conditions, which are applicable to all engagements VHL performs and which were enclosed with the submission form. These General Conditions can also be reviewed at www.vhlgenetics.com. The work VHL performs is based on the material and/or data it receives from its principal. This report may only be copied in its entirety. The organization is ISO:9001 certified for all her work. This test is based on PCR technology.



dr. van haeringen laboratorium b.v.

a **VHLGenetics** company

D. Mioch, MSc Veterinary Medicine
CEO

VHL exercises the utmost care in performing each of its engagements. No party other than the principal may derive any rights from the results of these engagements, and the principal expressly indemnifies VHL in respect of any third-party claims. VHL policy provides that any complaints must be received within eight days of the completion of an engagement and imposes restrictions on liability. In that respect, VHL refers to its General Conditions, which are applicable to all engagements VHL performs and which were enclosed with the submission form. These General Conditions can also be reviewed at www.vhlgenetics.com. The work VHL performs is based on the material and/or data it receives from its principal. This report may only be copied in its entirety. The organization is ISO:9001 certified for all her work. This test is based on PCR technology.

(Certificate nr: H104713/Date of issue: 02.02.2022)

page 2 of 4



H699 - Hereditary Cataract 2 (HC) -HSF4

Explanation about the result:

NORMAL: The animal is free and has two healthy alleles. When used in breeding, this animal will not become ill due to the disease. It cannot spread the disease in the population.

CARRIER: The animal is carrier and has one healthy and one mutant (disease) allele. When used in breeding, 50 percent of the offspring will receive the disease allele. Carriers will not become ill.

AFFECTED: The animal is affected and has two mutant (disease) alleles. When used in breeding, all offspring will receive the mutant allele from this animal. Affected animals will become ill.

H724 - L2-HGA

Explanation about the result:

NORMAL: The animal is free and has two healthy alleles. When used in breeding, this animal will not become ill due to the disease. It cannot spread the disease in the population.

CARRIER: The animal is carrier and has one healthy and one mutant (disease) allele. When used in breeding, 50 percent of the offspring will receive the disease allele. Carriers will not become ill.

AFFECTED: The animal is affected and has two mutant (disease) alleles. When used in breeding, all offspring will receive the mutant allele from this animal. Affected animals will become ill.

H811 - Hyperuricemia (HUU)

Explanation about the result:

NORMAL: The animal is free and has two healthy alleles. When used in breeding, this animal will not become ill due to the disease. It cannot spread the disease in the population.

CARRIER: The animal is carrier and has one healthy and one mutant (disease) allele. When used in breeding, 50 percent of the offspring will receive the disease allele. Carriers will not become ill.

AFFECTED: The animal is affected and has two mutant (disease) alleles. When used in breeding, all offspring will receive the mutant allele from this animal. Affected animals will become ill.

H673 - Degenerative Myelopathy (DM)

Explanation about the result:

NORMAL: The animal is free and has two healthy alleles. When used in breeding, this animal will not become ill due to the disease. It cannot spread the disease in the population.

CARRIER: The animal is carrier and has one healthy and one mutant (disease) allele. When used in breeding, 50 percent of the offspring will receive the disease allele. Carriers will not become ill.

AFFECTED: The animal is affected and has two mutant (disease) alleles. When used in breeding, all offspring will receive the mutant allele from this animal. Affected animals will become ill.

This test is based on an association study.

H847 - Coat Colour D-Locus Improved (MLPH)

Detailed information about Coat Colours and Coat Variation is available at www.combibreed.com.

Direct link: <https://www.combibreed.com/en-gb/Info-results/Coat-colour-and-variation/Dog>

H919 - Hiplaxity 1

The disease is of multifactorial origin, which means that the symptoms are a combination of genetic factors as well as the environment.

This marker is part of a panel of genetic factors influencing hip laxity. For each genetic factor of a multifactorial disease, the desirable genetic variant is indicated as 'N/N'. Animals carrying one

VHL exercises the utmost care in performing each of its engagements. No party other than the principal may derive any rights from the results of these engagements, and the principal expressly indemnifies VHL in respect of any third-party claims. VHL policy provides that any complaints must be received within eight days of the completion of an engagement and imposes restrictions on liability. In that respect, VHL refers to its General Conditions, which are applicable to all engagements VHL performs and which were enclosed with the submission form. These General Conditions can also be reviewed at www.vhlgenetics.com. The work VHL performs is based on the material and/or data it receives from its principal. This report may only be copied in its entirety. The organization is ISO:9001 certified for all her work. This test is based on PCR technology.



dr. van haeringen laboratorium b.v.

a VHLGenetics company

copy of the undesirable genetic variant are indicated as 'N/HL', whereas animals carrying two copies of the undesirable genetic variant are indicated as 'HL/HL'.

H421 - Hiplaxity 2

The disease is of multifactorial origin, which means that the symptoms are a combination of genetic factors as well as the environment.

This marker is part of a panel of genetic factors influencing hip laxity. For each genetic factor of a multifactorial disease, the desirable genetic variant is indicated as 'N/N'. Animals carrying one copy of the undesirable genetic variant are indicated as 'N/HL', whereas animals carrying two copies of the undesirable genetic variant are indicated as 'HL/HL'.

VHL exercises the utmost care in performing each of its engagements. No party other than the principal may derive any rights from the results of these engagements, and the principal expressly indemnifies VHL in respect of any third-party claims. VHL policy provides that any complaints must be received within eight days of the completion of an engagement and imposes restrictions on liability. In that respect, VHL refers to its General Conditions, which are applicable to all engagements VHL performs and which were enclosed with the submission form. These General Conditions can also be reviewed at www.vhlgenetics.com. The work VHL performs is based on the material and/or data it receives from its principal. This report may only be copied in its entirety. The organization is ISO:9001 certified for all her work. This test is based on PCR technology.

(Certificate nr: H104713/Date of issue: 02.02.2022)

page 4 of 4 <end of report>